This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

ZFP - Beta-Thalassemia

Biogen, Inc.

Drug Names(s): ZFP - Beta-Thalassemia, SB-BCLmR-HSPC

Description: ZFP Therapeutic for beta-thalassemia uses Sangamo's zinc finger nuclease (ZFN) gene-editing technology to modify a patient's own hematopoietic stem cells (HSCs), thereby eliminating the need for a matched donor.

Normally in infancy, fetal hemoglobin fully protects beta-thalassemia patients from developing disease symptoms. Later in childhood however, production of fetal hemoglobin ceases and is replaced by synthesis of adult-type beta-globin chains that are defective in beta-thalassemia patients. ZFP Therapeutic enables a patient's cells to permanently produce therapeutic fetal hemoglobin to achieve normal levels of hemoglobin and RBCs. The company has not disclosed the precise genetic target.

The process involves mobilization of the patient's cells into the blood stream prior to collection.

Deal Structure: Biogen and Sangamo
In January 2014, Biogen Idec and Sangamo BioSciences announced an exclusive worldwide collaboration and license agreement focused on the development of therapeutics for hemoglobinopathies, inherited conditions that result from the abnormal structure or underproduction of hemoglobin. The agreement will enable Biogen Idec to further enhance its expertise in non-malignant hematology by leveraging Sangamo's proprietary genome-editing technology platform to develop treatments targeting sickle cell disease (SCD) and beta-thalassemia.

Under the terms of the agreement, Sangamo is responsible for all research and development activities through the first clinical proof of concept trial in beta-thalassemia, and both companies will perform activities to enable submission of an Investigational New Drug (IND) application for SCD. Biogen Idec will be responsible for subsequent worldwide clinical development and commercialization of products arising from the...See full deal structure in Biomedtracker

Partners: Sangamo Biosciences, Inc.


ZFP - Beta-Thalassemia News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug